@article{ref1,
title="Sports doping: Emerging designer and therapeutic beta2-agonists",
journal="Clinica chimica acta: international journal of clinical chemistry",
year="2013",
author="Fragkaki, A. G. and Georgakopoulos, C. and Sterk, S. and Nielen, M. W. F.",
volume="425",
number="",
pages="242-258",
abstract="beta2-Adrenergic agonists, or β2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel β2-agonists molecules either by modifying the molecule of known β2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.<p /> <p>Language: en</p>",
language="en",
issn="0009-8981",
doi="10.1016/j.cca.2013.07.031",
url="http://dx.doi.org/10.1016/j.cca.2013.07.031"
}